Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs.
Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs.
Enrolls First Patients in Pivotal Clinical Trial of SQ109 for Multi-Drug Resistant Tuberculosis (MDR-TB)
develops an innovative drug SQ109 for MDR-TB treatment
The first drug in the company's portfolio is SQ109 for the treatment of multidrug-resistant TB (MDR-TB).
The drug is in advanced stage of clinical development.
Load more
The second drug Q203 is the first in new class
of amide imidazopyridine compounds. The drug is
a highly selective inhibitor of M. tuberculosis growth.
Load more
To date the Company develops 2 antituberculosis drugs: SQ109 and Q203.
Infectex Ltd., a portfolio company of Maxwell Biotech Venture Fund (MBVF) today announced the successful completion of a Phase I clinical trial of an oral formulation of Q203 for the treatment of tuberculosis. The product is developed by Infectex in Russia/CIS under a license from Qurient Co. Ltd. (South Korea). The trial was a single-center, […]
0 comments
Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), today announced positive results of a Phase 2b-3 clinical study of SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is a new small molecule drug discovered by scientists at Sequella, Inc. (USA) and the US […]
0 comments
The results were presented by principal investigator Prof. S.E.Borisov in his report “Effectiveness and safety of new anti-tuberculosis product SQ109” in Scientific and Practical Conference “Innovation Technologies in Phthisiology” (Moscow, November 24, 2016). Results presented in the report demonstrate satisfactory profile of safety and tolerability of SQ109 as well as the increase in effectiveness of […]
0 comments
Russian and Korean biotech companies Infectex, Ltd. and Qurient, Ltd. have announced a license agreement granting Infectex exclusive rights to develop and commercialize Qurient’s Tuberculosis-fighting drug Q203 in the Russian Federation, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan and Ukraine. Infectex is a portfolio company of Maxwell Biotech Venture Fund, created with the […]
0 comments
Infectex, a Russian biotech company in Maxwell Biotech Venture Fund’s portfolio announced today enrollment of the first patients in its Phase IIb-III clinical trial of SQ109 for MDR-TB. Infectex was founded in 2011 to develop and commercialize innovative products for the treatment of TB. The study, which will be conducted at specialized clinical centers in […]
0 comments
TV Center A Skolkovo resident Infectex, a portfolio company of Maxwell Biotech Venture Fund, established with the participation of RVC develops an innovative drug SQ109 for the multidrug-resistant tuberculosis (MDR-TB) treatment together with an American biotech company Sequella. Prof. Sergey Borisov, chief study coordinator, deputy director for science and clinical work at Moscow Research Center […]
0 comments
SQ109 will be evaluated for efficacy on multi-drug resistant patients Infectex has recently received notification from the Russian Ministry of Health for approval to begin the pivotal clinical trial associated with a drug registration submission, and can now proceed with the clinical development of SQ109 for treatment of tuberculosis (TB) in the Russian Federation. A […]
0 comments
A biotech company Infectex is the second portfolio company of Maxwell Biotech Venture Fund to receive the resident status in the Innovation Center of the Skolkovo Foundation. Infectex, Ltd. is a Russian innovative company, a member of the biotech holding Maxwell Biotech Group. The main activity of Infectex is aimed at development and market promotion […]
0 comments